ERBB2 and breast cancer: pCR associated with improvement in disease-free survival (DFS);8 despite of this, TNBC had poorer overall outcome compared with patients with luminal subtypes or HER2- positive breast cancer because additional adjuvant treatments are not available for them.9,10